newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Markets Insider
Hepcludex injection to treat chronic hepatitis delta virus infection in adults without cirrhosis.
The FDA has approved Hepcludex (bulevirtide) for treating chronic hepatitis delta virus in adults.
KEY POINTS
Bulevirtide is the first treatment specifically approved by the FDA for chronic HDV infection.
Hepcludex is approved for adults with chronic HDV both with and without compensated cirrhosis.
Until this approval, no FDA-approved therapies existed for patients with chronic hepatitis delta infection.
The FDA approval was granted to Gilead Sciences, Inc.
The U.S. Food and Drug Administration approved Hepcludex injection to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. Bulevirtide is the first FDA-approved treatment for chronic HDV infection, a serious and life-threatening condition that can cause rapid development of liver fibrosis, liver cancer, liver failure, and even death. “Today’s approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available,” said Wendy Carter, D.O., Acting Director of the Office of Infectious Diseases in FDA’s Center for Drug Evaluation and Research. “For individuals living with this chronic viral infection, this new treatment option offers hope in managing a disease that can rapidly progress to serious liver complications.” The FDA granted the approval to Gilead (GILD) Sciences, Inc.
Meet Samuel – Your Personal Investing Prophet